

Press release

## Genomtec Secures Over EUR 9 Million to Advance Commercialization Strategy and AI-Powered Diagnostics Development

**Wrocław, Poland – June 8, 2026** – Genomtec S.A. (WSE: GMT), a molecular diagnostics technology company, has strengthened its financial position with a EUR 2.6 million equity financing, bringing its total available funding from grants and newly raised capital to more than EUR 9 million.

The proceeds will support the commercialization and strategic partnering of Genomtec's proprietary diagnostic platforms, Genomtec ID® and OncoSNAAT®, while also accelerating the development of artificial intelligence tools designed to streamline molecular test development.

The financing follows strong investor demand and provides the company with resources to advance ongoing business development and licensing discussions with potential international partners.

*"We are pleased to have secured additional capital that enables us to execute the next phase of our commercialization strategy," said Miron Tokarski, CEO and co-founder of Genomtec. "With funding secured, we can continue advancing strategic discussions around Genomtec ID and OncoSNAAT while investing in technologies that strengthen our competitive position, including AI-based solutions for molecular diagnostics development."*

In parallel, Genomtec is executing a nearly EUR 1.65 million AI-focused project funded by the Lower Silesian Intermediate Body. The initiative applies artificial intelligence and machine learning to automate the design of LAMP-based primers, significantly reducing the time and cost required to develop new molecular diagnostic tests.

The company will also continue advancing:

- Commercialization and strategic partnering activities for Genomtec ID® and OncoSNAAT®;
- Further optimization of the Genomtec ID® platform;
- Development of OncoSNAAT®, a liquid biopsy-based oncology diagnostics technology.

Genomtec's flagship Genomtec ID® platform enables rapid molecular diagnostics at the point of care through a portable system combining proprietary SNAAT® technology with integrated testing capabilities. The company's OncoSNAAT® technology is being developed to support precision oncology through the detection of clinically relevant cancer-related genetic alterations.

---

### About Genomtec:

Genomtec is a MedTech company specializing in developing advanced technologies in the field of genetic diagnostics. The company's flagship project is the Genomtec ID mobile diagnostic system. The system allows for quick and precise molecular analysis outside the laboratory environment, without the need for qualified laboratory personnel. The solution utilizes



microfluidic technology and proprietary, patented isothermal technology SNAAT®. Genomtec's technology is protected by nearly 20 patents in Europe, the US, and Japan, among others, and the company has over 30 patent applications pending.

The company has EU CE-IVD certification for the GenomtecID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections.

The company is headquartered in Wrocław. Genomtec also has a presence in the UK, where an office and part of its international research and engineering team are located.

More information is available on the company's website: [www.genomtec.com](http://www.genomtec.com)

**Media contact:**

Michał Wierzchowski

Tel.: +48 531 613 067

[michal.wierzchowski@ccgroup.pl](mailto:michal.wierzchowski@ccgroup.pl)

**Contact for investors:**

Agata Dzieciołowska

Tel.: +48 606 205 119

[agata.dzieciolowska@ccgroup.pl](mailto:agata.dzieciolowska@ccgroup.pl)